Browsing Tag
BBP-418
3 posts
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
BridgeBio Pharma weighs $1bn KKR, Sixth Street preferred equity deal as launch costs rise
BridgeBio Pharma may be preparing its balance sheet for three potential product launches, but the value of a $1 billion preferred equity deal will depend heavily on its undisclosed dividend, conversion and redemption terms.
The rare disease opportunity behind BridgeBio Pharma’s BBP-418 breakthrough (NASDAQ: BBIO)
BridgeBio Pharma advances BBP-418 after Phase 3 muscular dystrophy results. Could the therapy unlock a major rare disease opportunity? Read the full analysis.